Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $33.0M |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | 0.0% |
| R&D | $0 | $0 | $0 | $0 | $0 |
| Operating income | −$301 | −$2.5M | −$3.2M | −$552.0M | −$166.2M |
| EBITDA | −$4.3K | −$10.5M | −$12.5M | −$552.0M | −$166.2M |
| Net income | −$4.6K | $5.5M | $6.6M | −$130.7M | $24.3M |
| Net margin | — | — | — | — | 73.7% |
| EPS (diluted) | -0.96 | 0.26 | 1.20 | -0.02 | 3.55 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds DUNE.
No tracked institution reports a position in DUNE as of their last filing.
No one on the platform has traded DUNE yet.
| -0.20% |
| $915M |
| — |
| ESLAEstrella Immunopharma, Inc. | $1.03 | +4.80% | $44M | — |
| GBRGGoldenbridge Acquisition Limited | $6.11 | -13.71% | $22M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.